UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy-A Cohort Study

Frontiers in immunology, 2022-04, Vol.13, p.877477-877477

2022

Volltextzugriff (PDF)

EASIX for Prediction of Outcome in Hospitalized SARS-CoV-2 Infected Patients

Frontiers in immunology, 2021-06, Vol.12, p.634416-634416

2021

Volltextzugriff (PDF)

Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV

International journal of molecular sciences, 2022-01, Vol.23 (3), p.1029

2022

Volltextzugriff (PDF)

Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL

Cells (Basel, Switzerland), 2020-05, Vol.9 (5), p.1225

2020

Volltextzugriff (PDF)

Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial

Journal of hematology and oncology, 2023-07, Vol.16 (1), p.79-79, Article 79

2023

Volltextzugriff (PDF)

439 Cardiovascular safety of chimeric antigen receptor (CAR) T cell therapy

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A488-A488

2023

Volltextzugriff (PDF)

First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma

Biomarker research, 2023-10, Vol.11 (1), p.1-91, Article 91

2023

Volltextzugriff (PDF)

310 Targeted delivery of a VEGF-blocking scFv to enhance CAR-T cell potency

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A353-A353

2023

Volltextzugriff (PDF)

Completion rate and impact on physician–patient relationship of video consultations in medical oncology: a randomised controlled open-label trial

ESMO open, 2020-11, Vol.5 (6), p.e000912-e000912, Article e000912

2020

Volltextzugriff (PDF)

Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies

Nature reviews. Drug discovery, 2023-12, Vol.22 (12), p.976-995

2023

Volltextzugriff (PDF)

Easix Predicts Severe Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neuro-Toxicity Syndrome (ICANS) in Patients Receiving CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy

Blood, 2021-11, Vol.138 (Supplement 1), p.3861-3861

2021

Volltextzugriff (PDF)

Pre-transplant EASIX and sepsis after allogeneic stem cell transplantation

Intensive care medicine, 2022-06, Vol.48 (6), p.753-755

2022

Volltextzugriff (PDF)

Validation of pre-conditioning EASIX for prediction of sepsis after allogeneic stem cell transplantation

Intensive care medicine, 2023-11, Vol.49 (11), p.1408-1410

2023

Volltextzugriff (PDF)

Easix As Prediction Score before CAR-T Cells Vs Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed/Refractory (r/r) Large B Cell Lymphoma (LBCL)

Blood, 2020-11, Vol.136 (Supplement 1), p.11-12

2020

Volltextzugriff (PDF)

Easix before Conditioning Therapy Predicts Sepsis after Allogeneic Stem Cell Transplantation

Blood, 2021-11, Vol.138 (Supplement 1), p.1774-1774

2021

Volltextzugriff (PDF)

Combinatorial Effects of BH3 Mimetics and CAR T Cells Targeting T-Cell Lymphomas

Blood, 2022-11, Vol.140 (Supplement 1), p.499-500

2022

Volltextzugriff (PDF)

Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes

Med (New York, N.Y. : Online), 2022-08, Vol.3 (8), p.538-564

2022

Volltextzugriff (PDF)

Six-Month Follow-up for Infectious Complications after Lymphodepletion and Application of CD19-Chimeric Antigen Receptor T (CAR-T) Cell Therapy

Blood, 2021-11, Vol.138 (Supplement 1), p.4835-4835

2021

Volltextzugriff (PDF)

CD19.CAR-T Cell Analysis Using Flow Cytometry and PCR

Blood, 2021-11, Vol.138 (Supplement 1), p.4797-4797

2021

Volltextzugriff (PDF)

Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics

Science translational medicine, 2024-06, Vol.16 (750), p.eadk7640

2024

Volltextzugriff (PDF)

Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study

Leukemia, 2024-08, Vol.38 (11), p.2419-2428

2024

Volltextzugriff (PDF)

Abstract 34: Improving CAR T cell efficacy in pancreatic cancer using an in vivo CRISPR Cas9 screen

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.34-34

2024

Volltextzugriff (PDF)

Third-Generation Chimeric Antigen Receptor (CAR) T Cells in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) - Results from the Heidelberg Trial 1 (HD-CAR-1 trial)

Blood, 2021-11, Vol.138 (Supplement 1), p.1734-1734

2021

Volltextzugriff (PDF)

1 – 25 von 45

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(45)

Sprache

Englisch
(44)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy-A Cohort Study

EASIX for Prediction of Outcome in Hospitalized SARS-CoV-2 Infected Patients

Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV

Comprehensive proteomic profiling of serum extracellular vesicles in patients with colorectal liver metastases identifies a signature for non-invasive risk stratification and early-response evaluation

Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL

Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial

439 Cardiovascular safety of chimeric antigen receptor (CAR) T cell therapy

MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers

First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma

310 Targeted delivery of a VEGF-blocking scFv to enhance CAR-T cell potency

Completion rate and impact on physician–patient relationship of video consultations in medical oncology: a randomised controlled open-label trial

Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies

Easix Predicts Severe Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neuro-Toxicity Syndrome (ICANS) in Patients Receiving CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy

Pre-transplant EASIX and sepsis after allogeneic stem cell transplantation

Validation of pre-conditioning EASIX for prediction of sepsis after allogeneic stem cell transplantation

Easix As Prediction Score before CAR-T Cells Vs Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed/Refractory (r/r) Large B Cell Lymphoma (LBCL)

Easix before Conditioning Therapy Predicts Sepsis after Allogeneic Stem Cell Transplantation

Combinatorial Effects of BH3 Mimetics and CAR T Cells Targeting T-Cell Lymphomas

Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes

Six-Month Follow-up for Infectious Complications after Lymphodepletion and Application of CD19-Chimeric Antigen Receptor T (CAR-T) Cell Therapy

CD19.CAR-T Cell Analysis Using Flow Cytometry and PCR

Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics

Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study

Abstract 34: Improving CAR T cell efficacy in pancreatic cancer using an in vivo CRISPR Cas9 screen

Third-Generation Chimeric Antigen Receptor (CAR) T Cells in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) - Results from the Heidelberg Trial 1 (HD-CAR-1 trial)

Suchergebnisse filtern